Kura Oncology to Host Virtual Investor Event to Discuss ASH 2025 Data on Ziftomenib Triple Combination in Acute Myeloid Leukemia

miércoles, 3 de diciembre de 2025, 8:34 am ET1 min de lectura
KURA--

Kura Oncology will host a virtual investor event on December 8, 2025, to discuss data on the triplet combination of ziftomenib (KOMZIFTI) with venetoclax and azacitidine in newly diagnosed and relapsed/refractory acute myeloid leukemia. The event will feature management team members and lead investigators discussing data scheduled for presentation at the 67th American Society of Hematology Annual Meeting. The live webcast and replay will be available on the company's website.

Kura Oncology to Host Virtual Investor Event to Discuss ASH 2025 Data on Ziftomenib Triple Combination in Acute Myeloid Leukemia

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios